Clinical Trial Details
| Trial ID: | L7373 |
| Source ID: | NCT02891954 |
| Associated Drug: | Canagliflozin |
| Title: | Genetics of Response to Canagliflozin |
| Acronym: | |
| Status: | ACTIVE_NOT_RECRUITING |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Canagliflozin |
| Outcome Measures: | Primary: Urinary glucose excretion (during the time interval 24-48 hours after first administration of canagliflozin), Urine collection will be initiated 24 hours after initiation of canagliflozin treatment, and continued for an additional 24 hours., 24-48 hours | Secondary: Bone-related biomarkers, Serum phosphorus, FGF23, 1,25-dihydroxyvitamin D, PTH, P1NP, and beta-CTX, 48 hrs|Bone-related biomarkers, Serum phosphorus, FGF23, 1,25-dihydroxyvitamin D, PTH, P1NP, and beta-CTX, 120 hrs|Ketosis-related biomarkers, glucagon, acetoacetate, beta-hydroxybutyrate, 48 hrs|Ketosis-related biomarkers, glucagon, acetoacetate, beta-hydroxybutyrate, 120 hurs|Serum uric acid, Change in serum uric acid at 48 hours, 48 hrs|Serum uric acid, Change in serum uric acid at 120 hours, 120 hrs |
| Sponsor/Collaborators: | Sponsor: University of Maryland, Baltimore | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 700 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE |
| Start Date: | 2016-09 |
| Completion Date: | 2025-09-25 |
| Results First Posted: | |
| Last Update Posted: | 2024-11-05 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT02891954 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|